Spherix Global Insights research found that Cyltezo users are more prominent than any of the other recently launched adalimumab biosimilars, regardless of specialty due to its unique status as the sole FDA-approved biosimilar with interchangeability status!
What is prominent? Please define......
What is prominent? Please define......